Company intelligence / Profile preview

Neuracle Science

Seongbuk-gu, Seoul, South Koreaneuracles.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Neuracle Science has developed a pipeline of therapeutic candidates targeting neurodegenerative and neurological disorders. Their lead assets include NS101, NS200, and NS400 for conditions such as reactive gliosis and sensorineural hearing loss. The company leverages bioinformatics to identify novel gene/protein targets with the aim of developing disease-modifying therapies. No late-stage clinical results have been published yet; most programs are preclinical or early clinical

Therapeutic areas: GastroenterologyImmunologyNeurology
Modalities: Monoclonal antibodiesBiosimilarsSynthetic peptidesSmall moleculesAntibodiesGene/protein target discovery
Industry: Biotech

Drug pipeline

2 assets

NS101

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neuracle Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuracle Science.

Explore the full profile